Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma - Scorecard - MDSpire
Advertisement
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Clinical Scorecard: Impact of Intravenous Immunoglobulin (IVIG) Therapy on Infection-Free Survival in Patients Undergoing BCMA-Targeted Bispecific Antibody Treatment for Multiple Myeloma
At a Glance
Category
Detail
Condition
Relapsed/Refractory Multiple Myeloma treated with BCMA-targeted bispecific antibodies
Key Mechanisms
Profound humoral immunodeficiency due to B cell depletion, neutropenia, T and B-cell depletion, immune effector cell exhaustion leading to increased infection risk
Target Population
Patients with relapsed/refractory multiple myeloma receiving BCMA-targeted bispecific antibody therapy
Care Setting
Academic medical centers providing standard of care or investigational BCMA bsAb therapies
Key Highlights
BCMA-targeted bispecific antibodies show high efficacy but increase risk of serious infections and infection-related mortality.
Primary IVIG prophylaxis is variably recommended; evidence for its effectiveness in this setting is limited and conflicting.
This multi-institutional retrospective study evaluated infection outcomes in 225 patients receiving BCMA bsAb, comparing primary IVIG prophylaxis versus no primary IVIG.
Guideline-Based Recommendations
Diagnosis
Assess infection risk based on history of infections, baseline blood counts, inflammatory markers, and combination therapies.
Monitor for hypogammaglobulinemia in patients receiving BCMA-targeted therapies.
Management
Consider IVIG replacement therapy either as primary prophylaxis (before infection) or secondary prophylaxis (after infection) based on institutional guidelines.
Implement infection prophylaxis measures tailored to patient risk factors and therapy type.
Monitoring & Follow-up
Regularly monitor for infections using clinical, imaging, microbiological, and histopathological assessments.
Grade infections using CTCAE v5 criteria and monitor for CRS and ICANS per established consensus guidelines.
Risks
Heightened infection risk due to profound immunodeficiency from BCMA bsAb therapy.
Potential for infection-related morbidity and mortality despite IVIG prophylaxis.
Patient & Prescribing Data
225 patients with relapsed/refractory multiple myeloma treated with BCMA-targeted bispecific antibodies across five US academic centers.
41% received primary IVIG prophylaxis after bsAb initiation but before infection; 59% did not receive primary IVIG. Patients receiving non-BCMA bsAb were excluded due to lower infection risk.
Clinical Best Practices
Define primary IVIG prophylaxis as administration after bsAb start but before any documented infection.
Exclude patients receiving IVIG before bsAb therapy from primary prophylaxis analyses.
Use landmark and time-dependent statistical analyses to adjust for immortal-time bias in evaluating IVIG effectiveness.
Tailor infection prophylaxis strategies based on individual patient risk factors and evolving clinical evidence.
